valuation thoughts, page-116

I have also topped up over the last couple of trading days Tymmsy.
We started of with listing and the IP, CLTX CAR T or CHM 1101. The share price hit a high of 44 cents with that IP.

Since then, CHM have added and licensed CHM 2101 from the University of Pennsylvania, one of the top cell therapy centre's in the world.

CHM also have added the CORE-NK platform technology, with the CEO and Managing Director Jennifer Chow and Chairman and founder Paul Hopper saying that this will be transformative for CHM. So much here to look forward to that the market has not priced in, it's not funny. NK looking like the new frontier in treatment.

Put it all together and from the start with one asset at 40 cents plus to now having seven asset's in development at 27 cents. It's a still at these levels IMHO.
With there different analysis currently giving a value of 90 cents plus, what's not to like here.
GLTA.